Compare M & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | M | GRFS |
|---|---|---|
| Founded | 1830 | 1940 |
| Country | United States | Spain |
| Employees | 94189 | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | M | GRFS |
|---|---|---|
| Price | $23.81 | $9.37 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $19.89 | $10.15 |
| AVG Volume (30 Days) | ★ 6.1M | 449.7K |
| Earning Date | 12-03-2025 | 07-28-2022 |
| Dividend Yield | ★ 3.08% | 1.50% |
| EPS Growth | ★ 331.62 | N/A |
| EPS | ★ 1.71 | 0.64 |
| Revenue | ★ $22,712,000,000.00 | $8,821,017,248.00 |
| Revenue This Year | N/A | $5.36 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | ★ $13.85 | $18.49 |
| Revenue Growth | N/A | ★ 7.31 |
| 52 Week Low | $9.76 | $6.19 |
| 52 Week High | $24.41 | $11.14 |
| Indicator | M | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 59.64 |
| Support Level | $22.21 | $9.17 |
| Resistance Level | $23.85 | $9.57 |
| Average True Range (ATR) | 0.72 | 0.19 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 59.55 | 72.70 |
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.